Literatur
- 1
Breems D A, Van Putten W L, De
Greef G E. et al .
Monosomal
karyotype in acute myeloid leukemia: a better indicator of poor
prognosis than a complex karyotype.
J Clin Oncol.
2008;
26
4791-4797
- 2
Bussel J B, Cheng G, Saleh M N. et al .
Eltrombopag for the treatment of chronic
idiopathic thrombocytopenic purpura.
N Engl J Med.
2007;
357
2237-2247
- 3
Glynn R J, Danielson E, Fonseca R AH. et al .
A randomized trial of rosuvastatin in the
prevention of venous thromboembolism.
N Engl J Med.
2009;
360
1851-1861
- 4
Hallek M, Fingerle-Rowson G, Fink A -M. et al .
Immunochemotherapy with Fludarabine (F),
Cyclophosphamid and Rituximab (R) (FCR) versus Fludarabine and Cyclophosphamid
(FC) improves response rates and progression-free survival (PFS)
of previously untreated patients (pts) with advanced chronic lymphocytic
leukemia (CLL).
Blood.
2008;
112
, Abstract 325
- 5
Hulin C, Facon T, Rodon P. et
al .
Efficacy of Melphalan and Prednisone Plus Thalidomide
in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma:
IFM 01/01 Trial.
J Clin Oncol.
2009
May 18. [Epub ahead of print];
- 6
Kuter D J, Bussel J B, Lyons R M. et al .
Efficacy of romiplostim
in patients with chronic immune thrombocytopenic purpura: a double-blind randomised
controlled trial.
Lancet.
2008;
371
395-403
- 7
Palumbo A, Bringhen S, Liberati A M. et al .
Oral melphalan, prednisone, and thalidomide
in elderly patients with multiple myeloma: updated results of a
randomized controlled trial.
Blood.
2008;
112
3107-3114
- 8
Pfreundschuh M, Ziepert M, Reiser M. et al .
The role of radiotherapy to bulky disease
in the Rituximab Era: results from two prospective trials of the
German high grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for
elderly patients with DLBCL.
Blood.
2008;
112
, Abstract 584
- 9
San M iguel
JF, Schlag R, Khuageva N. et al, K VISTA Trial Investigators .
Bortezomib
plus melphalane and prednisone for initial treatment of multiple
myeloma.
N Engl J Med.
2008;
359
906-917
- 10
Sebban C, Brice P, Delarue R. et al .
Impact of rituximab and/or high-dose
therapy with autotransplant at time of relapse in patients with follicular
lymphoma: A GELA study.
J Clin Oncol.
2008;
26
3614-3620
- 11 Swerdlow S H, Campo E, Harris N L. et al .WHO classification of Tumours
of the Haematopoietic and Lymphoid Tissues. Geneva, Switzerland; WHO press 2008
- 12
Vidal L, Gafter-Gvili A, Leibovici L. et al .
Rituximab Maintenance for the Treatment
of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis
of Randomized Trials.
J Natl Cancer Inst.
2009;
101
248-255
- 13
Weigert O, Uysal A, Metzner B. et al .
Impact of Autologous Stem Cell Transplantation
and/or Rituximab on Outcome of Patients with Relapsed Follicular
Lymphoma – Retrospective Analysis of 2 Randomized Trials
of the German Low Grade Lymphoma Study Group (GLSG).
Blood.
2008;
112
, Abstract 2189
Prof. Dr. Martin Dreyling
Mdizinische Klinik III der Universität München – Großhadern
Marchioninistr. 15
81377 München
Phone: 089/7095-2202
Fax: 089/7095-2201
Email: martin.dreyling@med.uni-muenchen.de
